Squalene epoxidase, located on chromosome 8q24.1, is upregulated in 8q+ breast cancer and indicates poor clinical outcome in stage I and II disease

Gains of chromosomes 7p and 8q are associated with poor prognosis among oestrogen receptor-positive (ER+) stage I/II breast cancer. To identify transcriptional changes associated with this breast cancer subtype, we applied suppression subtractive hybridisation method to analyse differentially expressed genes among six breast tumours with and without chromosomal 7p and 8q gains. Identified mRNAs were validated by real-time RT–PCR in tissue samples obtained from 186 patients with stage I/II breast cancer. Advanced statistical methods were applied to identify associations of mRNA expression with distant metastasis-free survival (DMFS). mRNA expression of the key enzyme of cholesterol biosynthesis, squalene epoxidase (SQLE, chromosomal location 8q24.1), was associated with ER+ 7p+/8q+ breast cancer. Distant metastasis-free survival in stage I/II breast cancer cases was significantly inversely related to SQLE mRNA in multivariate Cox analysis (P<0.001) in two independent patient cohorts of 160 patients each. The clinically favourable group associated with a low SQLE mRNA expression could be further divided by mRNA expression levels of the oestrogen-regulated zinc transporter LIV-1. The data strongly support that SQLE mRNA expression might indicate high-risk ER+ stage I/II breast cancers. Further studies on tumour tissue from standardised treated patients, for example with tamoxifen, may validate the role of SQLE as a novel diagnostic parameter for ER+ early stage breast cancers.

[1]  Rafael A. Irizarry,et al.  A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .

[2]  K. Taylor,et al.  LIV-1 suppression inhibits HeLa cell invasion by targeting ERK1/2-Snail/Slug pathway. , 2007, Biochemical and biophysical research communications.

[3]  J. Bergh,et al.  Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. V. van Diest,et al.  Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry , 2004, British Journal of Cancer.

[5]  M. Polymeropoulos,et al.  Genes that co-cluster with estrogen receptor alpha in microarray analysis of breast biopsies , 2001, The Pharmacogenomics Journal.

[6]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[7]  K Vajda,et al.  [Prognostic factors in breast cancer]. , 1998, Orvosi hetilap.

[8]  R. Gelber,et al.  Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Astruc,et al.  Squalene epoxidase and oxidosqualene lanosterol-cyclase activities in cholesterogenic and non-cholesterogenic tissues. , 1977, Biochimica et biophysica acta.

[10]  Y. Fukushima,et al.  Localization of the squalene epoxidase gene (SQLE) to human chromosome region 8q24.1. , 1997, Genomics.

[11]  Horst Buerger,et al.  First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor‐positive breast cancer , 2005, The Journal of pathology.

[12]  Jan Mous,et al.  Touching base , 2000, Nature Genetics.

[13]  Ajay N. Jain,et al.  Breast tumor copy number aberration phenotypes and genomic instability , 2006, BMC Cancer.

[14]  M. Astruc,et al.  Squalene epoxidase, oxido-squalene cyclase and cholesterol biosynthesis in normal and tumoral mucosa of the human gastro-intestinal tract. Evidence of post-HHG CoA regulation. , 1981, Biochimica et Biophysica Acta.

[15]  Armin A. Weiser,et al.  Expression levels of the putative zinc transporter LIV‐1 are associated with a better outcome of breast cancer patients , 2005, International journal of cancer.

[16]  R. Nicholson,et al.  Zinc transporter LIV-1: a link between cellular development and cancer progression , 2004, Trends in Endocrinology & Metabolism.

[17]  M. Xiong,et al.  Recursive partitioning for tumor classification with gene expression microarray data , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  L. Belghiti,et al.  Prognostic factors in breast cancer , 2002 .

[19]  J. O’Shaughnessy,et al.  Molecular signatures predict outcomes of breast cancer. , 2006, The New England journal of medicine.

[20]  Ian O Ellis,et al.  The Emerging Role of the LIV-1 Subfamily of Zinc Transporters in Breast Cancer , 2007, Molecular medicine.

[21]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[23]  O. Haas,et al.  Felix Mitelman: Database of chromosome aberrations in cancer , 2002, Human Genetics.

[24]  Jonathan C. Cohen,et al.  Dual roles for cholesterol in mammalian cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Akashi-Tanaka,et al.  Prognostic and predictive factors in the adjuvant treatment of breast cancer , 2002, Breast cancer.

[26]  S. Tavaré,et al.  High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer , 2007, Genome Biology.

[27]  Robert J. Mayer,et al.  National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.

[28]  S. Edge,et al.  Prognostic factors in breast cancer , 2005 .

[29]  J. Massagué.  Sorting out breast-cancer gene signatures. , 2007, The New England journal of medicine.

[30]  Jorma Isola,et al.  Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. , 2003, Cancer research.